A closer look at “FDA Approves First-Ever Drug for Friedreich's Ataxia After 30-Year Wait”, exactly as the source publishes it. Food and Drug Administration has approved Skyclarys (omaveloxolone), the first treatment for Friedreich's ataxia, a rare inherited neurodegenerative disorder that typically emerges in childhood and progressively impairs coordination, muscle strength, and heart function. Developed by Reata Pharmaceuticals, the drug gained approval after a Phase 2 trial showed improved neurological function in patients, marking a historic shift from symptom management to disease modification. Friedreich's ataxia affects roughly 5,000 people in the U.S.
and 15,000 worldwide, with most patients relying on wheelchairs within 10 to 20 years of diagnosis. The approval follows decades of research and advocacy by organizations like the Friedreich's Ataxia Research Alliance, which helped fund early development. Skyclarys works by activating the Nrf2 pathway, reducing oxidative stress and improving mitochondrial function, addressing the underlying pathology. This listing links straight to the original page, where the content is available in full.